Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2007

01.04.2007 | Original Article

Performance Characteristics and Comparison of Two Fecal Occult Blood Tests in Patients Undergoing Colonoscopy

verfasst von: Marcia Cruz-Correa, Kathleen Schultz, Sanjay Jagannath, Mary Harris, Sergey Kantsevoy, Marshall Bedine, Anthony N. Kalloo

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

We investigated the use of a new type of FOBT (EZ-Detect) that uses the blood's pseudo-peroxidase activity as an enzymatic catalyst, in a one-step chromogen-substrate system performed by the patient. Asymptomatic patients ≥50 years old received three Hemoccult II (HO) cards and three EZ-Detect (EZ) packages to be used in three consecutive bowel movements. Sensitivity, specificity, positive predictive value, and negative predictive value for detection of colorectal neoplasia was calculated. The study included 207 patients, with a mean age of 58.9 years. Diagnostic accuracy for detection of adenomas was similar for the EZ and HO tests (66.7% vs. 71.0%; P=0.48), while for advanced adenomas diagnostic accuracy for the EZ and HO tests was 86.0% vs. 94.2% (P=0.01), respectively. Most patients preferred the EZ test (92% vs. 8%). We conclude that the EZ test has a diagnostic profile similar to that of the HO test for identification of adenomas; however, for advanced adenomas the diagnostic accuracy was slightly better for the HO. The EZ test was preferred by most patients, which may increase colorectal cancer screening compliance.
Literatur
1.
Zurück zum Zitat Bresalier RS, Kim YS (1998) Malignant neoplasms of the large intestine. In: Feldman M, Sleisenger MH, Scharschmidt BF, (eds.) Gastrointestinal disease, 6th ed. WB Saunders, Philadelphia, pp 1906–1939 Bresalier RS, Kim YS (1998) Malignant neoplasms of the large intestine. In: Feldman M, Sleisenger MH, Scharschmidt BF, (eds.) Gastrointestinal disease, 6th ed. WB Saunders, Philadelphia, pp 1906–1939
2.
Zurück zum Zitat Kronborg O, Fenger C, Olsen J, et al. (1996) Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348:1467–1471PubMedCrossRef Kronborg O, Fenger C, Olsen J, et al. (1996) Randomized study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348:1467–1471PubMedCrossRef
3.
Zurück zum Zitat Allison JE (2005) Colon cancer screening guidelines 2005: The fecal occult blood test option has become a better FIT. Gastroenterology 129:745–748PubMedCrossRef Allison JE (2005) Colon cancer screening guidelines 2005: The fecal occult blood test option has become a better FIT. Gastroenterology 129:745–748PubMedCrossRef
4.
Zurück zum Zitat Mandel JS, Bond JH, Church TR, et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328:1365–1371PubMedCrossRef Mandel JS, Bond JH, Church TR, et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328:1365–1371PubMedCrossRef
5.
Zurück zum Zitat Hardcastle JD, Chamberlain JO, Robinson MH, et al. (1996) Randomized controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348:1472–1477PubMedCrossRef Hardcastle JD, Chamberlain JO, Robinson MH, et al. (1996) Randomized controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348:1472–1477PubMedCrossRef
6.
Zurück zum Zitat Mandel JS, Church TR, Bond JH, et al. (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343:1603–1607PubMedCrossRef Mandel JS, Church TR, Bond JH, et al. (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343:1603–1607PubMedCrossRef
7.
Zurück zum Zitat Liberman D, Sleisenger MH (1996) It is time to recommend screening for colorectal cancer? Lancet 348:1463–1464CrossRef Liberman D, Sleisenger MH (1996) It is time to recommend screening for colorectal cancer? Lancet 348:1463–1464CrossRef
8.
Zurück zum Zitat Liberman DA (1990) Colon cancer screening. The dilemma of positive screening tests. Arch Intern Med 150:740–744CrossRef Liberman DA (1990) Colon cancer screening. The dilemma of positive screening tests. Arch Intern Med 150:740–744CrossRef
9.
Zurück zum Zitat Greenberg PD, Bertario L, Gnauck R, et al. (2000) A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 95:1331–1338PubMedCrossRef Greenberg PD, Bertario L, Gnauck R, et al. (2000) A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 95:1331–1338PubMedCrossRef
10.
Zurück zum Zitat Collins JF, Lieberman DA, Durbin TE, et al. (2005) Veterans Affairs Cooperative Study #380 Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 142(2):81–85PubMed Collins JF, Lieberman DA, Durbin TE, et al. (2005) Veterans Affairs Cooperative Study #380 Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 142(2):81–85PubMed
11.
Zurück zum Zitat Tate JJ, Northway J, Royle GT, et al. (1989) Evaluation of a “DIY” test for the detection of colorectal cancer. J R Soc Med 82:388–390PubMed Tate JJ, Northway J, Royle GT, et al. (1989) Evaluation of a “DIY” test for the detection of colorectal cancer. J R Soc Med 82:388–390PubMed
12.
Zurück zum Zitat Hou SI, Chen PH (2004) Home-administered fecal occult blood test for colorectal cancer screening among worksites in Taiwan. Prev Med 38:78–84PubMedCrossRef Hou SI, Chen PH (2004) Home-administered fecal occult blood test for colorectal cancer screening among worksites in Taiwan. Prev Med 38:78–84PubMedCrossRef
13.
Zurück zum Zitat Ahlquist DA, Wieand HS, Moertel CG, et al. (1993) Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant test. JAMA 269:1262–1267PubMedCrossRef Ahlquist DA, Wieand HS, Moertel CG, et al. (1993) Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant test. JAMA 269:1262–1267PubMedCrossRef
14.
Zurück zum Zitat St John DJB, Young GP, Alexeyeff MA, et al. (1993) Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 104:1661–1668PubMed St John DJB, Young GP, Alexeyeff MA, et al. (1993) Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 104:1661–1668PubMed
15.
Zurück zum Zitat Smith RA, Cokkinindes V, Eyre HJ (2004) American Cancer Society guidelines for early detection of cancer. Ca Cancer J Clin 54(1):41–52PubMedCrossRef Smith RA, Cokkinindes V, Eyre HJ (2004) American Cancer Society guidelines for early detection of cancer. Ca Cancer J Clin 54(1):41–52PubMedCrossRef
Metadaten
Titel
Performance Characteristics and Comparison of Two Fecal Occult Blood Tests in Patients Undergoing Colonoscopy
verfasst von
Marcia Cruz-Correa
Kathleen Schultz
Sanjay Jagannath
Mary Harris
Sergey Kantsevoy
Marshall Bedine
Anthony N. Kalloo
Publikationsdatum
01.04.2007
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9383-y

Weitere Artikel der Ausgabe 4/2007

Digestive Diseases and Sciences 4/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.